STOCK TITAN

Absci Corporation - $ABSI STOCK NEWS

Welcome to our dedicated page for Absci Corporation news (Ticker: $ABSI), a resource for investors and traders seeking the latest updates and insights on Absci Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Absci Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Absci Corporation's position in the market.

Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) announced positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program, at the 42nd Annual J.P. Morgan Healthcare Conference. The company's generative AI platform designed over 50 antibody leads with subnanomolar affinity, selecting three potential candidates for the ABS-101 program. The preclinical studies demonstrated properties consistent with a potentially superior product profile, supporting the program’s potential to create an efficacious candidate conducive to subcutaneous dosing. Absci expects to initiate Investigational New Drug application (IND) enabling studies for ABS-101 in February 2024, and submit an IND in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.47%
Tags
conferences clinical trial
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to participate in 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
conferences
Rhea-AI Summary
Absci (Nasdaq: ABSI) and PrecisionLife collaborate to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The partnership aims to create a pipeline of novel biotherapeutics for chronic diseases. Absci achieves its 2023 outlook of ten new Active Programs signed for the year through this collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
partnership AI
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) collaborates with AstraZeneca to develop an AI-designed antibody for oncology. The collaboration combines Absci's generative AI technology with AstraZeneca's expertise, aiming to accelerate the discovery of a potential new cancer treatment candidate. The agreement includes an upfront commitment, R&D funding, milestone payments, and royalties on product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
AI
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to present at Piper Sandler 35th Annual Healthcare Conference in New York, NY. The company's management will present on November 29th at 10:50 a.m. Eastern Time. Interested parties can access a live and archived webcast on the company’s investor relations website at investors.absci.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) entered into a partnership with Almirall to rapidly develop novel treatments for dermatological diseases, with a deal value of up to $664M plus royalties. They also unveiled an AI drug creation pipeline of four wholly-owned assets. The company reported financial and operating results for the quarter ended September 30, 2023, highlighting their recent achievements and the value of their AI Integrated Drug Creation™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) and Almirall S.A. (BME: ALM) announced a partnership to develop AI-designed therapeutics for chronic dermatological diseases. Absci's de novo generative AI technology will be used to create and commercialize therapeutic candidates for two dermatological targets, with potential upfront fees, R&D, and post-approval milestone payments of up to $650 million. The collaboration aims to deliver life-changing medicines to patients and represents Almirall's first de novo AI drug collaboration, marking a significant advancement in AI drug creation for dermatology and chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
partnership AI
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) will be participating in upcoming investor conferences in New York, NY. They will be hosting 1x1 meetings on November 8th and participating in fireside chats on November 15th and 16th. Interested parties can access webcasts on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
Rhea-AI Summary
Absci Corporation announces speaker lineup for R&D Day on October 4th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
Absci Corporation

Nasdaq:ABSI

ABSI Rankings

ABSI Stock Data

565.42M
80.69M
22.65%
37.86%
9.3%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
VANCOUVER